FLT3 and acute myeloid leukemia: To do so, we took advantage of a small cohort of FLT3-ITD AML patients, which we have previously classified in two main groups according to the ITD insertion site: 3 FLT3ITD-TKD patients (carrying the ITD in the TKD domain) and 3 FLT3ITD-JMD+ITD-TKD patients (carrying the ITD in the JMD and TKD domain) [8] (Fig. S2).